

Clinical Trial Protocol

Iranian Registry of Clinical Trials

28 May 2026

Evaluation of changes in urinary parameters after oral administration of magnesium chlorides and potassium citrate in pediatric with calcium oxalate urolithiasis.

Protocol summary

Summary

The objective of the present study is to investigate changes in urinary parameters after oral administration of magnesium chlorides and potassium citrate in pediatrics with calcium oxalate urolithiasis. In this interventional, semi-experimental, and prospective study, 30 patients, aged 1-18 years old, for whom the urinary tract stone diagnosis confirmed by the clinical symptoms or ultrasonography by a specialist, will be recruited. The patients will receive the potassium citrate solution for 4 weeks as the first phase and then solution of potassium citrate and chloride magnesium for another 4 weeks as the second phase. A sample of 24-hour urine and blood sample will be taken and calcium, potassium, Na, Cl, citrate, oxalate, Phosphate, creatinine, and magnesium will be checked before the study and after each phase and the results compared between the groups.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT138707091282N1**

Registration date: **2011-04-12, 1390/01/23**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2011-04-12, 1390/01/23

Registrant information

Name

Alaleh Gheissari

Name of organization / entity

Isfahan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 31 1250 2462

Email address

gheisari@med.mui.ac.ir

Recruitment status

Recruitment complete

Funding source

Isfahan University of Medical Sciences and Health Services

Expected recruitment start date

2008-02-02, 1386/11/13

Expected recruitment end date

2011-01-01, 1389/10/11

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of changes in urinary parameters after oral administration of magnesium chlorides and potassium citrate in pediatric with calcium oxalate urolithiasis.

Public title

Evaluation of changes in urinary parameters after oral administration of magnesium chlorides and potassium citrate in pediatric with calcium oxalate urolithiasis.

Purpose

Prevention

Inclusion/Exclusion criteria

Inclusion criteria: age 2-12 years with possibility of calcium oxalate kidney stone, No past history of peptic ulcer, chronic diarrhea or cardiac disease, primary hyperparathyroidism, consumption of anticonvulsants,

No proven history of disorders affecting tubular ion excretion such as: recent urinary tract infection , distal renal tubular acidosis , chronic pyelonephritis, renal dysfunction and obstructive uropathy Exclusion criteria: Patients who did not complete all steps of the study, refusing to consume either potassium citrate or magnesium chloride

Age

From **2 years** old to **18 years** old

Gender

Male

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: **40**

Randomization (investigator's opinion)

N/A

Randomization description**Blinding (investigator's opinion)**

Not blinded

Blinding description**Placebo**

Used

Assignment

Single

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Isfahan University of Medical Sciences and Health Services

Street address

Isfahan University of Medical Sciences, Hezarjarib St., Isfahan

City

Isfahan

Postal code**Approval date**

2008-08-20, 1387/05/30

Ethics committee reference number

286004

Health conditions studied**1****Description of health condition studied**

urolithiasis

ICD-10 code

N20

ICD-10 code description

Calculus of kidney and ureter

Primary outcomes**1****Description**

Urine parameter (Ca-K-Na-Cl-Cit-Ox-P-Cr-Mg)

Timepoint

Before and 4 weeks after intervention

Method of measurement

24-hour urine test

2**Description**

Blood parameter (Ca-K-Na-Cl-Cit-Ox-P-Cr-Mg)

Timepoint

Before and 4 weeks after intervention

Method of measurement

blood test

Secondary outcomes

empty

Intervention groups**1****Description**

Phase 1: Oral solution of potassium citrate, 0.5 cc/kg/dose, every 8 hours, 30 min after meal, for 4 weeks

Category

Treatment - Drugs

2**Description**

Phase 2: Combination of K Citrate 0.5 cc/kg/dose, every 8 hours, 30 min after meal as well as Mg Chloride 10-20 mg/kg/dose equivalent to 180 meq elemental Mg for 4 weeks

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Isfahan University of Medical Sciences

Full name of responsible person**Street address**

Isfahan University of Medical Sciences, Hezarjarib St., Isfahan

City

Isfahan

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Isfahan University of Medical Sciences and Health Services

Full name of responsible person

Dr Alaleh Gheisary

Street address

Isfahan University of Medical Sciences, Hezarjarib St., Isfahan

City

Isfahan

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Isfahan University of Medical Sciences and Health Services

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Isfahan University of Medical Sciences and Health Services

Full name of responsible person

Dr Alaleh Gheisary

Position

Pediatric Dep., Isfahan University of Medical Sciences

Other areas of specialty/work**Street address**

Isfahan University of Medical Sciences, Hezarjarib St., Isfahan

City

Isfahan

Postal code**Phone**

+98 913 313 3563

Fax**Email**

gheisari@med.mui.ac.ir

Web page address

Person responsible for scientific

inquiries

Contact

Name of organization / entity

Isfahan University of Medical Sciences and Health Services

Full name of responsible person

Dr Alaleh Gheisary

Position

Pediatrics Nephrology Spacialist

Other areas of specialty/work**Street address**

Isfahan University of Medical Sciences, Hezarjarib St., Isfahan

City

Isfahan

Postal code**Phone**

+98 913 313 3563

Fax**Email**

gheisari@med.mui.ac.ir

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Isfahan University of Medical Sciences and Health Services

Full name of responsible person

Amin Ziaee

Position

MD student

Other areas of specialty/work**Street address**

Isfahan University of Medical Sciences, Hezarjarib St., Isfahan

City**Postal code****Phone****Fax****Email****Web page address**

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty